Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07828652) titled 'Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World)' on Sept. 2.

Study Type: Observational

Primary Sponsor: Yeon Hee Park

Condition: TNBC - Triple-Negative Breast Cancer

Intervention: Other: Medical record use research

Recruitment Status: Not recruiting

Date of First Enrollment: September 14, 2026

Target Sample Size: 2000

To know more, visit https://clinicaltrials.gov/study/NCT07828652

Disclaimer: Curated by HT Syndication....